Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency

Hyperhidrosis Primary Focal Axilla Clinical Trial

Official title:

Clinical Evaluation of the Safety and Efficacy of the InMode RF Pro System With the Morpheus8 Applicator (With the 24 Pin Tip) for the Treatment of Primary Focal Hyperhidrosis of the Axillae Using Fractional RF Technology

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05860972
• Other study ID #: DO611232A
• Status: Recruiting
• Phase: N/A
• Start date: March 9, 2023
• Est. completion date: April 2026

Study information

• Verified date: June 2023
• Source: InMode MD Ltd.
• Contact: Meital Matalon, MS
• Phone: 949 258-8870
• Email: meital.matalon[@]inmodemd.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae

Description:

Study subjects will be consecutively screened and enrolled into the study. The study will consist of an active group that will receive 2 treatments with the InMode radio frequency Pro System with the Morpheus8 Applicator (with the 24 pin tip) and a sham group that will receive 2 sham treatments with the same InMode radio frequency Pro System and Morpheus8 Applicator (with a sham 24 pin tip). Treatment will be performed in a preheated controlled environment (T°≥22°C). Follow up visits will occur at 1 month, 3 months, and 6 months post treatment

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: April 2026
• Est. primary completion date: April 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subject is 18 years of age or older at the time of consent.

• Subject reports a quality-of-life rating of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS).

• Subject has primary focal axillary hyperhidrosis evidenced by at least 6 months of visible, detectable, focal, exaggerated sweating without any apparent explanation and at least two of the following:

• Bilateral and relatively symmetric

• Impairs daily activities

• Frequency of at least one episode per week

• Age of onset less than 25 years old

• Positive family history

• Cessation of focal sweating during sleep

• Subject is willing and able to comply with protocol requirements and all study visits

• Willing to have de-identified images of the treated areas taken for possible use in publications and presentations.

• Subject understands the study and has provided written informed consent

Exclusion Criteria:

Subject has secondary hyperhidrosis due to medications, infections, malignancy or endocrinopathy.

• Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.

• Severe concurrent conditions such as cardiac disorders epilepsy, uncontrolled hypertension, and liver or kidney diseases.

• Any active skin condition in the treatment area, such as sores, psoriasis, eczema and rash.

• Swollen axillary lymph nodes.

• History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.

• Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.

• History of bleeding coagulopathies or use of anticoagulants in the last 10 days.

• Prior endoscopic thoracic sympathectomy, liposuction or other surgery for hyperhidrosis in the treated area. Injection of botulinum toxin in the treated area within one year

• Use of Isotretinoin (Accutane®) within 6 months prior to study

• Oral anticholinergic medication use (e.g., Robinul) or cholinomimetic medication use within the last 4 weeks or planned use during the study's follow up phase.

• Currently participating in or recently participated in another clinical trial (within the last 30 days).

• History of or current neurologic deficit in the treatment limb.

• Known resistance to or history of difficulty with local anesthesia (lidocaine with epinephrine).

• Current or history of cancer, including skin cancer, or premalignant moles.

• Injury in the treatment area or any other condition that, in the opinion of the investigator, might make treatment unsafe.

• Subject has a pacemaker, defibrillator or other electronic implant anywhere in the body.

• Permanent implant in the treated area such as metal plates, screws and metal piercing or silicon.

• Females who are pregnant or nursing

• Female subjects of childbearing potential not willing to use an acceptable form of contraception for the duration of the study.

Related Conditions & MeSH terms

• Hyperhidrosis
• Hyperhidrosis Primary Focal Axilla

Intervention

Device:
• Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment

Locations

Country	Name	City	State
Israel	RAMBAM Medical Center	Haifa
United States	Dallas Plastic Surgery Institute	Dallas	Texas
United States	Southeastern Dermatology	Knoxville	Tennessee
United States	Skinfluence	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
InMode MD Ltd.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A statistically significant difference in the percent of responders defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2 at the 4-week	A statistically significant difference in the percent of responders, defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2 at the 4-week follow-up visit, in the treatment group compared to the sham group	4 weeks
Secondary	Percent of subjects with a perspiration intensity of 0-2 on the Minor's starch-iodine test Intensity	Percent of subjects with a perspiration intensity of 0-2 on the Minor's starch-iodine test Intensity Visual Scale at the 4-week follow-up visit in the treatment group compared to the sham group	4 weeks
Secondary	Percent of responders, defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2	Percent of responders, defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2 at the 12-week follow-up visit in the treatment group compared to the sham group.	12 weeks
Secondary	Percent of subjects who achieved a 2-point or greater decline in the Hyperhidrosis Disease Severity Scale.	Percent of subjects who achieved a 2-point or greater decline in Hyperhidrosis Disease Severity Scale. from baseline at 4 weeks follow-up in the treatment group compared to the sham group	4 weeks